You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Govt ready to roll out vaccine within 10 days of emergency nod: Health secy

Health personnel succh as doctors and nurses and frontline workers such as police personnel, home guards won't have to register themselves online to get the vaccine

Centre | Coronavirus Vaccine | Health Ministry

BS Reporter  |  New Delhi 

Coronavirus, vaccine, covid, drugs, clinical trials
Manufacturers will air transport will transfer the vaccine to four large depots which are the primary vaccine stores in Karnal, Mumbai, Chennai and Kolkata.

The is prepared to roll out the Covid vaccine within 10 days of the emergency use authorisation, which was granted to two companies on January 3. While giving this information on Tuesday, Health Secretary Rajesh Bhushan told reporters that the final date would be decided by the government. The roll-out is being planned, including the logistics and technology network, based on the feedback from the recent dry run of the vaccination process, according to Bhushan. Aadhar verification too will be a part of the online vaccine delivery platform Co-Win.

Addressing the weekly briefing on Covid, Bhushan said health workers including doctors and nurses as well as frontline workers such as police personnel and home guards would not have to register on the online platform to get vaccinated. Their data has already been uploaded on the Co-Win vaccine delivery management system.

ALSO READ: Vaccine firms Bharat Biotech, Serum Institute patch up after war of words

For people above 50 years of age and those with co-morbidities, a committee of health experts is studying the linkages between diseases and increased mortality if there is a Covid infection. The committee will suggest who among this group will be given top priority and how the vaccine will be rolled out for them. “We are almost there...we have very eminent people working on it,” V K Paul, member-health, Niti Aayog, said.

In the backdrop of all the controversy around vaccine approval, Paul mentioned that scientific rigour, statutory requirements and regulatory norms had been followed while giving restricted use authorization to the two vaccine candidates — Covishield and Covaxin.

ALSO READ: Govt clears air on Bharat Biotech's vaccine, says relied on safety data

Besides (manufacturing the AstraZeneca-Oxford vaccine) and Bharat Biotech, Pfizer-BioNtech too applied for emergency approval of vaccine. However, US pharma major is yet to make a presentation to the subject expert committee (SEC). “has been given three opportunities, but they have not appeared before the SEC...SEC is willing to listen to their presentation,” Bhushan said.


Detailing the plan, Bhushan pointed out that vaccine manufacturers would transfer the vaccine to four large depots in Karnal, Mumbai, Chennai and Kolkata. From these depots, the vaccine will travel through refrigerated vans to 37 state vaccine stores. These are places where vaccines can reach in bulk. Thereafter, it will travel to temperature-controlled facilities across districts before reaching primary

Aiding the journey and storage of vaccine will be digitally-monitored networks and temperature trackers. And at the of it all will be a server, where information will be uploaded real time, according to Bhushan. The Co-Win platform is being upgraded to cater to a target group of 300 million individuals. Beneficiaries will be given an option to generate a unique health ID while registering for vaccination. This health ID is part of the government’s national digital health mission.

The online system will also require verification “to prevent malpractice’’. The software is being upgraded to improve its user interface based on the feedback received from the dry run for vaccine administration held on January 2. Bhushan also said the average recovered cases from Covid-19 have exceeded average daily new cases for the last five weeks. Of the total active cases, 43.96 per cent patients were in healthcare facilities, while 56.04 per cent were in home isolation.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, January 05 2021. 19:22 IST